Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (4)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
Avelox - labeled renal guidance
Source retrieved 2026-11-07 - confirm current applicability
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
Avelox - product and source limitations
This summary covers systemic oral therapy. Check the full fluoroquinolone warnings and the infection indication.
How to use this: Verify the current prescribing information for this presentation.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Avelox - labeled renal guidance
Moxifloxacin (Avelox), adult oral tablets
Method: Clinical renal category or population named in the cited section
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content
Original GlobalRPh protocol
Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/moxifloxacin/
Usual Dosing (Adults)
400 mg orally or IV every 24 hours. Complicated intra-abdominal infection begins with IV treatment; convert to oral when appropriate without adjusting dose. Source durations: bacterial sinusitis 10 days; bronchitis exacerbation 5 days; community-acquired pneumonia 7-14 days; uncomplicated skin infection 7 days; complicated skin infection 7-21 days; complicated intra-abdominal infection 5-14 days.
GRPH-moxifloxacin-01 · Source section: Usual Dosing (Adults)Renal section finder
Renal method: Clinical renal category or population named in the cited section Source date: DailyMed SPL version 6, effective 2011-12-13; posted Dec 15, 2011 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
No renal reduction is required, including in hemodialysis and continuous ambulatory peritoneal dialysis (CAPD). This summary covers systemic oral therapy. Check the full fluoroquinolone warnings and the infection indication.
RDM73-avelox-official-1 · Source locator: Renal guidance: 8.6 and 12.3
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method: No routine kidney-function reduction in the source. Source date: Revision date not stated in the reviewed page. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
Adults receive 400 mg IV or orally once daily in this institutional regimen. The same dose is listed for renal dysfunction and dialysis. This guidance concerns systemic formulations, not ophthalmic moxifloxacin.
Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.
